To better identify people with long COVID, researchers have identified 12 distinguishing symptoms and have developed a symptom-based scoring system.

A new study published in NEJM adds to the growing body of research on the effectiveness of ketamine for treatment-resistant depression (TRD). Results from the ELEKT-D randomized trial found that when it came to improving treatment-resistant major depression in outpatients without psychotic features, ketamine worked just as well as electroconvulsive therapy (ECT).

A new report from IQVIA Institute for Human Data Science estimates that of 7,310 prescription drugs legally dispensed to U.S. patients between January 2017 to December 2022, roughly 70% (5,085) were being actively marketed and sold by illegal online pharmacies.

A new survey from Wolters Kluwer Health reflects increasing trust in providers in non-traditional primary care settings.

FDA has approved buprenorphine extended-release injection (Brixadi—Braeburn) for the treatment of moderate to severe opioid use disorder (OUD). The drug is available as a weekly dose for patients who have started treatment with a single dose of a transmucosal buprenorphine product and as a monthly version for patients already being treated with buprenorphine.